Trial Profile
A phase II, open-label study of the clinical activity, safety, and tolerability of lapatinib in combination with bevacizumab in subjects with advanced or metastatic ErbB2-overexpressing breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Bevacizumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 07 Jan 2021 Status changed from active, no longer recruiting to completed.
- 29 Aug 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 25 Jun 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.